Andrea Rocha S Mont'Alverne1, Rosa Maria R Pereira2, Lucas Yugo S Yamakami1, Vilma Santos T Viana1, Edmund Chada Baracat1, Eloisa Bonfá1, Clovis Artur Silva1. 1. From the Division of Rheumatology, the Gynecology Department, and the Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.A.R.S. Mont'Alverne, MD; R.M.R. Pereira, MD, PhD, Division of Rheumatology; L.Y.S. Yamakami, MD, PhD, Gynecology Department; V.S.T. Viana, PhD, Division of Rheumatology; E.C. Baracat, MD, PhD, Gynecology Department; E. Bonfá, MD, PhD, Division of Rheumatology; C.A. Silva, MD, PhD, Division of Rheumatology, Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo. 2. From the Division of Rheumatology, the Gynecology Department, and the Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.A.R.S. Mont'Alverne, MD; R.M.R. Pereira, MD, PhD, Division of Rheumatology; L.Y.S. Yamakami, MD, PhD, Gynecology Department; V.S.T. Viana, PhD, Division of Rheumatology; E.C. Baracat, MD, PhD, Gynecology Department; E. Bonfá, MD, PhD, Division of Rheumatology; C.A. Silva, MD, PhD, Division of Rheumatology, Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo. rosamariarp@yahoo.com.
Abstract
OBJECTIVE: To assess ovarian reserve markers in patients with Takayasu arteritis (TA). METHODS: Twenty patients with TA and 24 healthy controls were evaluated for ovarian reserve by follicle-stimulating hormone, luteinizing hormone, and estradiol, and antral follicle count (AFC). Anti-Müllerian hormone (AMH) was measured by ELISA using 2 different kits. Demographical data, menstrual abnormalities, disease variables, and treatment were also analyzed. RESULTS: The median current age was similar in patients with TA and controls (31.2 ± 6.1 vs 30.4 ± 6.9 yrs, p = 0.69). The frequencies of decreased levels of AMH in patients with TA were identical using both kits and higher when compared to controls (50% vs 17%, p = 0.02; 50% vs 19%, p = 0.048). A positive correlation was observed between the 2 kits in patients with TA (r = +0.93, p < 0.0001) and in healthy controls (r = +0.93, p < 0.0001). The apparent lower AFC (11 vs 16, p = 0.13) and the higher frequency of low AFC (41% vs 22%, p = 0.29) in TA compared to controls did not reach statistical significance. Other hormones were similar in both groups (p > 0.05). Further evaluation of patients with TA with low AMH levels (< 1.0 ng/ml) versus normal AMH levels (> 1.0 ng/ml) revealed that the frequency of current disease activity (p = 1.0) and the median of erythrocyte sedimentation rate (p = 0.6), C-reactive protein (p = 0.4), prednisone cumulative dose (p = 0.8), and methotrexate cumulative dose (p = 0.8) were comparable in both groups. Cyclophosphamide use was reported in only 1 patient with reduced ovarian reserve, whereas none of the remaining patients received gonadotoxic drugs. CONCLUSION: To the best of our knowledge, our present study was the first to suggest that patients with TA may have diminished ovarian reserve.
OBJECTIVE: To assess ovarian reserve markers in patients with Takayasu arteritis (TA). METHODS: Twenty patients with TA and 24 healthy controls were evaluated for ovarian reserve by follicle-stimulating hormone, luteinizing hormone, and estradiol, and antral follicle count (AFC). Anti-Müllerian hormone (AMH) was measured by ELISA using 2 different kits. Demographical data, menstrual abnormalities, disease variables, and treatment were also analyzed. RESULTS: The median current age was similar in patients with TA and controls (31.2 ± 6.1 vs 30.4 ± 6.9 yrs, p = 0.69). The frequencies of decreased levels of AMH in patients with TA were identical using both kits and higher when compared to controls (50% vs 17%, p = 0.02; 50% vs 19%, p = 0.048). A positive correlation was observed between the 2 kits in patients with TA (r = +0.93, p < 0.0001) and in healthy controls (r = +0.93, p < 0.0001). The apparent lower AFC (11 vs 16, p = 0.13) and the higher frequency of low AFC (41% vs 22%, p = 0.29) in TA compared to controls did not reach statistical significance. Other hormones were similar in both groups (p > 0.05). Further evaluation of patients with TA with low AMH levels (< 1.0 ng/ml) versus normal AMH levels (> 1.0 ng/ml) revealed that the frequency of current disease activity (p = 1.0) and the median of erythrocyte sedimentation rate (p = 0.6), C-reactive protein (p = 0.4), prednisone cumulative dose (p = 0.8), and methotrexate cumulative dose (p = 0.8) were comparable in both groups. Cyclophosphamide use was reported in only 1 patient with reduced ovarian reserve, whereas none of the remaining patients received gonadotoxic drugs. CONCLUSION: To the best of our knowledge, our present study was the first to suggest that patients with TA may have diminished ovarian reserve.
Authors: Amy L Winship; Lauren R Alesi; Sneha Sant; Sherene Loi; Karla J Hutt; Jessica M Stringer; Aldana Cantavenera; Teharn Hegarty; Carolina Lliberos Requesens; Seng H Liew; Urooza Sarma; Meaghan J Griffiths; Nadeen Zerafa; Stephen B Fox; Emmaline Brown; Franco Caramia; Pirooz Zareie; Nicole L La Gruta; Kelly-Anne Phillips; Andreas Strasser Journal: Nat Cancer Date: 2022-08-25
Authors: Ali Ovayolu; Özkan Özdamar; İsmet Gün; Cansev Y Arslanbuğa; Tayfun Kutlu; Gülden Tunalı; Ramazan Uluhan Journal: Int J Clin Exp Med Date: 2015-06-15
Authors: Fernando Henrique Carlos de Souza; Clovis Artur da Silva; Lucas Yugo Shiguehara Yamakami; Vilma dos Santos Trindade Viana; Eloisa Bonfá; Samuel Katsuyuki Shinjo Journal: Clin Rheumatol Date: 2015-09-07 Impact factor: 2.980
Authors: Ali Şahin; Savaş Karakuş; Yunus Durmaz; Çağlar Yıldız; Hüseyin Aydın; Ahmet Kıvanç Cengiz; Duygu Güler Journal: Int J Rheumatol Date: 2015-05-12
Authors: A N Schüring; T Fehm; K Behringer; M Goeckenjan; P Wimberger; M Henes; J Henes; M F Fey; M von Wolff Journal: Arch Gynecol Obstet Date: 2017-11-24 Impact factor: 2.344